OA17472A - Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment. - Google Patents
Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment. Download PDFInfo
- Publication number
- OA17472A OA17472A OA1201500352 OA17472A OA 17472 A OA17472 A OA 17472A OA 1201500352 OA1201500352 OA 1201500352 OA 17472 A OA17472 A OA 17472A
- Authority
- OA
- OAPI
- Prior art keywords
- albumin
- fusion protein
- binding
- arginine deiminase
- cancer
- Prior art date
Links
- 108010082340 EC 3.5.3.6 Proteins 0.000 title claims abstract description 133
- 201000011510 cancer Diseases 0.000 title claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 101710027066 ALB Proteins 0.000 title claims description 88
- 102100001249 ALB Human genes 0.000 title claims description 88
- 229940050528 albumin Drugs 0.000 title claims description 79
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 139
- 102000037240 fusion proteins Human genes 0.000 claims abstract description 139
- 239000004475 Arginine Substances 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 20
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims abstract description 10
- 201000007270 liver cancer Diseases 0.000 claims abstract description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 230000001419 dependent Effects 0.000 claims abstract description 7
- 235000019750 Crude protein Nutrition 0.000 claims abstract description 5
- 206010024324 Leukaemias Diseases 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 4
- 201000005216 brain cancer Diseases 0.000 claims abstract description 4
- 201000005202 lung cancer Diseases 0.000 claims abstract description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims abstract description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 3
- 201000011231 colorectal cancer Diseases 0.000 claims abstract description 3
- 201000004101 esophageal cancer Diseases 0.000 claims abstract description 3
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 3
- 206010017758 Gastric cancer Diseases 0.000 claims abstract 2
- 201000011549 stomach cancer Diseases 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 235000018102 proteins Nutrition 0.000 claims description 37
- 230000004927 fusion Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 241000204028 Mycoplasma arginini Species 0.000 claims description 11
- 229940075612 Bacillus cereus Drugs 0.000 claims description 8
- 241000193755 Bacillus cereus Species 0.000 claims description 8
- 150000007970 thio esters Chemical class 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 230000017730 intein-mediated protein splicing Effects 0.000 claims description 5
- 230000001404 mediated Effects 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 241000194035 Lactococcus lactis Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000194036 Lactococcus Species 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 241000202956 Mycoplasma arthritidis Species 0.000 claims description 2
- 241000204048 Mycoplasma hominis Species 0.000 claims description 2
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 claims description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 241001223182 Pseudomonas plecoglossicida Species 0.000 claims description 2
- 241000589776 Pseudomonas putida Species 0.000 claims description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 claims description 2
- 229940031000 Streptococcus pneumoniae Drugs 0.000 claims description 2
- 229940076156 Streptococcus pyogenes Drugs 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036499 Half live Effects 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 206010027476 Metastasis Diseases 0.000 abstract description 2
- 230000002195 synergetic Effects 0.000 abstract description 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 2
- 108091006822 Human Serum Albumin Proteins 0.000 abstract 2
- 235000009697 arginine Nutrition 0.000 description 47
- 210000004027 cells Anatomy 0.000 description 35
- 239000000047 product Substances 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 15
- 102000004512 Argininosuccinate Synthase Human genes 0.000 description 12
- 108020001811 Argininosuccinate Synthase Proteins 0.000 description 12
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 235000013477 citrulline Nutrition 0.000 description 11
- 229960002173 citrulline Drugs 0.000 description 11
- 206010025650 Malignant melanoma Diseases 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 206010008342 Cervix carcinoma Diseases 0.000 description 8
- 201000010881 cervical cancer Diseases 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000024881 catalytic activity Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102000009042 Argininosuccinate lyases Human genes 0.000 description 6
- 108091000035 Argininosuccinate lyases Proteins 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 101700011961 DPOM Proteins 0.000 description 6
- 101710029649 MDV043 Proteins 0.000 description 6
- 101700061424 POLB Proteins 0.000 description 6
- 101700054624 RF1 Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000003963 colon carcinoma Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 210000001519 tissues Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 210000003000 Inclusion Bodies Anatomy 0.000 description 4
- 229920000272 Oligonucleotide Polymers 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000004143 urea cycle Effects 0.000 description 4
- QXZGLTYKKZKGLN-UHFFFAOYSA-M 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoate Chemical compound [O-]C(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-M 0.000 description 3
- 108020001204 Arginases Proteins 0.000 description 3
- 102000004452 Arginases Human genes 0.000 description 3
- 241000194108 Bacillus licheniformis Species 0.000 description 3
- 230000035633 Metabolized Effects 0.000 description 3
- 241000204003 Mycoplasmatales Species 0.000 description 3
- 230000037289 Plasma half life Effects 0.000 description 3
- 230000037240 Plasma half-life Effects 0.000 description 3
- 101700044827 RNMT Proteins 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- FSEUPUDHEBLWJY-HWKANZROSA-N Diacetylmonoxime Chemical compound CC(=O)C(\C)=N\O FSEUPUDHEBLWJY-HWKANZROSA-N 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000003470 Mitochondria Anatomy 0.000 description 2
- 241000202944 Mycoplasma sp. Species 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010075480 ADI PEG20 Proteins 0.000 description 1
- 102100009713 AZIN2 Human genes 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 229960004198 Guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 230000036223 MICHAELIS CONSTANT Effects 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 210000000441 Neoplastic Stem Cells Anatomy 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 101700053997 adc1 Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N aminothiourea Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 108091000080 arginine decarboxylase Proteins 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000000779 depleting Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- XKUUMWKWUZRRPD-UHFFFAOYSA-N heptan-2-amine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.CCCCCC(C)[NH3+].CCCCCC(C)[NH3+] XKUUMWKWUZRRPD-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005569 modified proteins Proteins 0.000 description 1
- 102000035365 modified proteins Human genes 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Abstract
The present invention provides a pharmaceutical composition containing albuminbinding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis.
Description
PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-BINDING ARGININE DEIMINASE FOR CANCER TARGETING TREATMENT
Cross-reference to Related Application [0001] The présent application claims benefit from US provisional patent application serial number 61/773,214 filed March 6, 2013 and US non-provisional patent application serial number 14/197,236 filed March 5, 2014, and the disclosures of which are incorporated herein by reference in its entirety.
Technical Field [0002] The présent invention describes albumin-binding arginine deiminase (AAD) fusion protein that has been genetically modified to create a material having high activity and long in vivo half-life. The présent invention further describes the designs for DNA and protein engineering for creating different AAD fusion proteins. The AAD fusion proteins can be isolated and purified from soluble fraction and insoluble fraction (inclusion bodies) of the crude proteins. The présent invention further relates to albumin-binding arginine deiminase-containing pharmaceutical compositions for cancer targeting treatment and curing arginine-dependent diseases in humans and other animais.
Background of the Invention [0003] The incidence of pancreatic cancer, colon cancer, liver cancer, melanoma and cervical cancer in the worldwide population is increasing. Effective treatments for these diseases are urgently needed. In many types of cancer including leukemia, melanoma, pancreatic, colon, rénal cell carcinoma, lung, prostate, breast, brain, cervical and liver cancers, the cancer cells are auxotrophic for arginine since they lack of expression of argininosuccinate synthetase (ASS), making these cancers excellent targets for arginine déplétion therapy.
[0004] Arginine is a semi-essential amino acid for humans and other mammals. It can be synthesized from citrulline via a two step process catalyzed by the urea cycle enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL). Arginine can be metabolized to omithine by the enzyme arginase, and omithine can be converted to citrulline by omithine carbamoyltransferase (OTC) in the mitochondria. The citrulline can be utilized to synthesize arginine again. Normal cells usually do not require an exogenous supply of arginine for growth because of the abundant catalytic activity of ASS and ASL. In contrast, many types of cancers do not express ASS and therefore are auxotrophic for arginine. Their growth is dépendent on arginine solely obtained from blood circulation. Therefore, targeting circulating arginine by using arginine-degrading enzymes is a feasible strategy to inhibit ASS-negative tumor growth [Feun et al., Curr. Pharm. Des. 14:1049-1057 (2008); Kuo et al., Oncotarget. 1:246-251 (2010)] [0005] Arginine can be degraded by arginase, arginine decarboxylase, and arginine deiminase (ADI). Among them, arginine deiminase (ADI) appears to hâve the highest affmity for arginine (a low Km value). ADI converts arginine to citrulline and ammonia, the métabolites of the urea cycle. Unfortunately, ADI can only be found in prokaryotes e.g. Mycoplasma sp. There are some problems associated with the isolation and purification of ADI from prokaryotes. ADI isolated from Pseudomonas pudita fails to exhibit efficacy in vivo because of its low enzymatic activity in neutral pH. ADI produced from Escherichia coli is enzymatically inactive and subsequently requires multiple dénaturation and renaturation process which raises the subséquent cost of production.
[0006] As the native ADI is found in microorganisms, it is antigenic and rapidly cleared from circulation in a patient. The native form of ADI is immunogenic upon injection into human circulation with a short half-life (~4 hours) and elicits neutralizing antibodies [Ensor et al., Cancer Res. 62:5443-5450 (2002); Izzo et al., J. Clin. Oncol. 22:1815-1822 (2004)]. These shortcomings can be remedied by pegylation. Among various forms of pegylated ADI, ADI bound with PEG (molecular weight 20,000) via succinimidyl succinate (ADI-PEG 20) has been found to be an effïcacious formulation. However, the activity of ADI after pegylation is greatly decreased on the order of 50% [Ensor et al., Cancer Res. 62:5443-5450 (2002)]. The previous attempts to create pegylated ADI resulted in materials that are not homogenous (due to the random attachment of PEG on protein surface Lys residues) and also difficult to characterize and perform quality control during the manufacturing process. Also, PEG is very expensive, greatly increasing the production cost. After the intravenous injection of pegylated ADI in vivo, leakage or detachment of free PEG is observed and the ADI (without PEG) can elicit the immunogenicity problem. Therefore, there is a need for improved cancer-treatment compositions, particularly, improved cancer-treatment compositions that hâve enhanced activity and in vivo half-life. Ύ
Summary of the Invention [0007] In the présent invention, albumin-binding arginine deiminase (AAD) fusion protein has increased its activity and plasma half-life in order to efficiently deplete arginine in cancer cells. Native ADI may be found in microorganisms and is antigenic and rapidly cleared from circulation in a patient. The présent invention constructs different AAD fusion proteins with one or two albumin-binding proteins to maintain high activity with longer in vivo half-life (at least 5 days of arginine déplétion after one injection). In the présent invention, the albumin binding protein in the AAD fusion protein product does not appear to influence its spécifie enzyme activity but instead appears to increase the circulating half-life. The spécifie activities of wildtype ADI and AAD fusion protein in the présent invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively.
[0008] In its broadest sense, the présent invention provides an albumin-binding arginine deiminase fusion protein comprising a first portion comprising one or two components selected from an albumin-binding domain, an albumin-binding peptide or an albumin-binding protein(s) fused to a second portion comprising arginine deiminase to form the albumin-binding arginine deiminase fusion protein such that the albumin-binding arginine deiminase fusion protein retains the activity of arginine deiminase and is also able to bind sérum albumin.
[0009] The présent invention further relates to albumin-binding arginine deiminase (AAD) fusion protein -containing pharmaceutical compositions for targeted cancer treatment in humans and other animais. The first aspect of the présent invention is to construct the modified AAD fusion protein with high activity against cancer cells. The second aspect of the présent invention is to purify AAD fusion protein with high purity from both soluble and insoluble fractions of the crude proteins. The third aspect of the présent invention is to lengthen the half-life of AAD fusion protein as it can bind to albumin very well in the circulation. The fourth aspect of the présent invention is to provide a method of using the AAD-containing pharmaceutical composition of the présent invention for treating cancer by administering said composition to a subject in need thereof suffering from various tumors, cancers or diseases associated with tumors or cancers or other arginine-dependent diseases.
[0010] The AAD fusion protein of the présent invention is also modified to avoid dissociation into albumin-binding protein and ADI such that it becomes more stable and has a longer half-life in circulation. ADI is fused to an albumin-binding domain/peptide/protein in AAD fusion product to extend the plasma half-life and reduce the immunogenicity of the fusion product. γ
Albumin binding domain (ABD) is a peptide that binds albumin in the blood. There are different variants of ABD showing different or improved human sérum albumin (HSA) affmities.
Different variants of ABD can be constructed and can be fused to ADI. Unlike the naturally occurring ADI, this longer half-life property facilitâtes the déplétion of arginine efficiently in cancerous cells, cancer stem cells and/or cancer progenitor cells.
[0011] The pharmaceutical composition containing AAD fusion protein can be used for intravenous (i.v.) injection (for rapid-acting dosage of médication) and intramuscular (i.m.) injection (for fairly rapid-acting and long-lasting dosage of médication). The application of AAD fusion protein in the présent invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, prostate cancer, cervical cancer, liver cancer, nasopharyngeal cancer, esophageal cancer and brain cancer. The présent invention is directed to AAD fusion proteins, to methods of treating cancer, to methods of treating and/or inhibiting metastasis of cancerous tissue, and to methods of curing arginine-dependent diseases.
[00 f 2] The method of the présent invention also includes using a combination of different chemotherapeutic drugs and/or radiotherapy with the AAD fusion protein of the présent invention to give a synergistic effect on cancer treatment.
Brief Description of the Drawings [0013] FIG. 1 shows the design approach for construction of different AAD fusion proteins with one or two albumin-binding domain/peptide/protein(s) in three-dimensional structure. One or two albumin-binding domain/peptide/protein(s) can be fused to ADI to form the AAD fusion protein. The position of albumin-binding domain/peptide/protein is far from the ADI active site. The albumin-binding domain/peptide/protein can be fused to the N-terminus or/and C-terminus of ADI. The structure in this figure is based on the Mycoplasma arginini ADI structure (Protein Data Bank: 1LXY). (A) Native ADI; (B) AAD fusion protein with two ABD or ABD1; (C) AAD fusion protein with one ABD or ABD1 at N-terminus; (D) AAD fusion protein with one ABD or ABD1 at C-terminus.
[0014] FIG. 2 shows the sequence alignment for ADI in some bacterial species including Mycoplasma arginini (SEQ ID No. 23), Lactococcus lactis (SEQ ID No. 24), Bacillus cereus (SEQ ID No. 25) and Bacillus licheniformis (SEQ ID No. 26).
[0015] FIG. 3 shows the designs and amino acid sequences for different AAD fusion proteins originated from Mycoplasma arginini (A to E) and AAD fusion protein originated from Bacillus cereus (F).
[0016] FIG. 4 shows the création of AAD fusion protein in two embodiments (A) and (B) by the use of intein-fusion proteins and expressed protein ligation (CBD, chitin binding domain) under the following schemes; (C) C-terminal fusion; (D) N-terminal fusion; (E) Intein-mediated protein ligation.
[0017] FIG. 5 shows the plasmid map of the expression vector constructed for producing AAD fusion protein.
[0018] FIG. 6 shows the (A) gene map, (B) nucléotide sequence (SEQ ID No. 44) and (C) amino acid sequence (SEQ ID No. 40) of His-ABD-PolyN-ADI. (ADI: the Mycoplasma arginini ADI) [0019] FIG. 7 shows the (A) gene map, (B) nucléotide sequence (SEQ ID No. 45) and (C) amino acid sequence (SEQ ID No. 41) of His-ABD-PolyN-bcADI. (bcADI, the Bacillus cereus ADI) [0020] FIG. 8 shows the expression and purification of AAD fusion protein: (A) AAD is -90% soluble when expressed at 20°C (lanes 2 and 3) and -90% insoluble (inclusion body) when expressed at 37°C (lanes 4 and 5); (B) The purified AAD fusion protein in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel: lane 1, purified AAD fusion protein (52.8 kDa); lane 2, molecular weight marker.
[0021] FIG. 9 illustrâtes that AAD fusion protein depletes arginine efficiently and inhibits the growth of various types of human cancer cell lines in in vitro tissue culture studies, including human melanoma (A375), human colon carcinoma (HCT116), and human pancreatic cancer (Panel).
[0022] FIG. 10 shows the albumin binding results of AAD fusion protein: (A) A non-denaturing native polyacrylamide gel (12%) showing the increase in the amount of HSA+AAD complex when the amount of AAD fusion protein (the amino acid sequence is shown in SEQ ID NO: 36; FIG. 3A) added increases. The mole ratios of human sérum albumin (HSA): AAD in lanes 3-6 are 1:1, 1:2, 1:5, and 1:15, respectively. Lanes 1 and 2 represent HSA and AAD at 6 and 30 pmole, respectively; (B) In another experiment based on AAD fusion protein (SEQ ID NO: 40; FIG. 3E), an albumin: AAD ratio of 1:8 is sufficient to bind ail the albumin présent (lane 5).
[0023] FIG. 11 is a graph showing the dose response of AAD fusion protein on plasma arginine levels in mice. A dose of 100 pg of AAD is sufficient to deplete plasma arginine for at least 5 days.
Définitions [0024] The term “cancer stem cell” refers to the biologically distinct cell within the neoplastic clone that is capable of initiating and sustaining tumor growth in vivo (i.e. the cancer-initiating cell).
Detailed Description of the Invention [0025] Arginine is a semi-essential amino acid for humans and other mammals. It can be synthesized from citrulline via a two step process catalyzed by urea cycle enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL). Arginine can be metabolized to omithine by the enzyme arginase, and omithine can be converted to citrulline by omithine carbamoyltransferase (OTC) in the mitochondria. The citrulline can be utilized to synthesize arginine again. Normal cells do not typically require an exogenous supply of arginine for growth because of the abundant catalytic activity of ASS and ASL. In contrast, many types of cancers do not express ASS and are therefore auxotrophic for arginine. Their growth is solely dépendent on arginine from circulation. Therefore, targeting circulating arginine by using arginine-degrading enzymes is a feasible strategy to inhibit ASS-negative tumor growth.
[0026] Arginine can be degraded by arginine deiminase (ADI). ADI converts arginine to citrulline and ammonia, the métabolites of the urea cycle. Unfortunately, ADI can only be found in prokaryotes e.g. Mycoplasma sp. There are many problems associated with the isolation and purification of arginine deiminase from prokaryotes. ADI isolated from Pseudomonas pudita failed to exhibit efficacy in vivo because of its low enzymatic activity in neutral pH. ADI produced from Escherichia coli is enzymatically inactive and subsequently requires multiple dénaturation and renaturation process which raised the subséquent cost of production. The plasma half-life of the native form of ADI is short (~4 hours) upon injection into human circulation [Ensor et al., Cancer Res. 62:5443-5450 (2002); Izzo et al., J. Clin. Oncol. 22:18151822 (2004)]. These shortcomings can be partially remedied by pegylation. Among various forms of pegylated ADI, ADI bound with PEG (molecular weight 20,000) via succinimidyl succinate (ADI-PEG 20) has been found to be an efficacious formulation. However, the activity of ADI after pegylation is greatly decreased (by -50%) [Ensor et al., Cancer Res. 62:5443-5450 (2002); Wang et al., Bioconjug. Chem. 17:1447-1459 (2006)]. Also, the succinimidyl succinate PEG linker can easily be hydrolyzed and detached from the protein, causing immunogenic problems after a short period of use in the body. Therefore, there is a need for improved cancertreatment compositions, particularly, improved cancer-treatment compositions with enhanced activity.
[0027] ADI isolated from P. pudita failed to exhibit efficacy in vivo because it had little enzyme activity at a neutral pH and was rapidly cleared from the circulation of experimental animais. ADI derived from Mycoplasma arginini is described, for example, by Takaku et al, Int. J. Cancer, 51:244-249 (1992), and U.S. Pat. No. 5,474,928. However, a problem associated with the therapeutic use of such a heterologous protein is its antigenicity. The chemical modification of ADI from Mycoplasma arginini, via a cyanuric chloride linking group, with polyethylene glycol (PEG) was described by Takaku et al., Jpn. J. Cancer Res., 84:1195-1200 (1993). However, the modified protein was toxic when metabolized due to the release of cyanide from the cyanuric chloride linking group. In contrast, even for the ADI-PEG20, the PEG linker can easily be hydrolyzed and detached from the protein, causing immunogenic problems after a short period of use in the body. Therefore, there is a need for compositions which dégradé non-essential amino acids and which do not hâve the problems associated with the prior art.
[0028] In many types of cancer including melanoma, pancreatic, colon, leukemia, breast, prostate, rénal cell carcinoma and liver cancers, cancer cells are auxotrophic for arginine since they lack of expression of argininosuccinate synthetase (ASS), making them excellent targets for arginine déplétion therapy. In this invention, albumin-binding arginine deiminase (AAD) fusion proteins hâve high activity with long half-lives for efficient déplétion of arginine in cancer cells.
[0029] The size of the monomer for ADI is on the order of 45 kDa and it exists as dimer (on the order of 90 kDa) [Das et al., Structure. 12:657-667 (2004)]. A design for construction of an AAD fusion protein is shown in FIG. 1. One or two albumin-binding domain/peptide/protein(s) with or without linker(s), SEQ ID NO: 46-49, are fused to ADI to form the AAD fusion protein. It is noteworthy that the sélection of one or two particular albumin-binding domain/peptide/protein(s) can be made depending upon the type of cancer tissue to be targeted, the desired size and halflife of the resulting fusion protein, and whether a domain or entire protein is selected. Further, vi the selected albumin-binding material may be the same or different. That is, a protein and a peptide can be fused, two proteins, two domains, a domain and a protein, etc., as long as the résultant molécule retains the activity of the ADI and is also able to bind sérum albumin with neither function of one portion of the fusion protein being interfered with by the other portion of the fusion protein. The position of the albumin-binding domain/peptide/protein is far from the active site. The albumin-binding domain/peptide/protein can be fused to the N-terminus or/and C-terminus of ADI. There are different variants of ABD showing different or improved human sérum albumin (HSA) affmities. Different variants of ABD can be constructed and can be fused to ADI. Some micro-organisms endowed with ADI (for example Pseudomonas sp) cannot be used, due to their potential pathogenicity and pyrogenicity. The source of ADI can be from, but not limited to, different microorganisms, e.g. Mycoplasma (e.g. Mycoplasma arginini, Mycoplasma arthritidis, Mycoplasma hominis), Lactococcus (e.g. Lactococcus lactis), Pseudomonas (e.g. Pseudomonas plecoglossicida, Pseudomonas putida, Pseudomonas aeruginosa), Steptococcus (e.g. Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pneumoniae), Escherichia, Mycobacterium (e.g. Mycobacterium tuberculosis) and Bacillus (e.g. Bacillus licheniformis, Bacillus cereus). It is preferred that ADI is cloned from Mycoplasma arginini, Lactococcus lactis, Bacillus licheniformis, Bacillus cereus, or any combination thereof. Their amino acid sequences with SEQ ID (SEQ ID NO: 23-35) and the sequence alignment for some of the amino acid sequences in FIG. 2 are disclosed herein and also in the literature [Das et al., Structure. 12:657-667 (2004); Wang et al., Bioconjug. Chem. 17:1447-1459 (2006); Ni et al., Appl. Microbiol. Biotechnol. 90:193-201 (2011)].
[0030] The design and amino acid sequence for (A) native Mycoplasma arginini ADI protein (SEQ ID NO: 23), (B) different AAD fusion proteins originated from the Mycoplasma arginini ADI (SEQ ID NO: 36-40) and (C) AAD fusion protein originated from the Bacillus cereus ADI (SEQ ID NO: 41) are shown in FIG. 3. Different AAD fusion proteins are successfully constructed. A linker is inserted between the albumin-binding protein and ADI in the AAD fusion protein in these embodiments.
[0031 ] On the other hand, a novel AAD fusion protein is also created by the use of intein-fusion proteins and expressed protein ligation (FIG. 4). The novel AAD fusion protein can be formed (1) by reacting the ADI having a N-terminal cysteine residue with a reactive thioester at C-terminus of the ABD, or (2) by reacting the ABD having a N-terminal cysteine residue with a reactive thioester at C-terminus of the ADI so that the ADI and the ABD are linked by a covalent bond,
In FIG. 4E, ADI with N-terminal cysteine residue reacts with reactive thioester at the C-terminus of ABD. The thioester tag at the C-terminus of ABD, and an α-cysteine at the N-terminus of ADI are required to facilitate protein ligation. These fragments are produced using a pTWIN l vector (New England Biolabs) according to the manufacturer’s manual. In particular, the gene coding for the ABD-Intein-CBD fusion protein is synthesized and it is cloned into the vector under the control of T7 promoter for expression in E. coli (FIG. 4C). The ABD-Intein-CBD fusion protein produced binds to chitin in a column. The amino acid sequence of ABD-InteinCBD (SEQ ID NO: 42) is shown in FIG. 4A. After thiol-inducible cleavage and elution from the column, the ABD with reactive thioester at its C-terminus is obtained (FIG. 4C). On the other hand, the gene coding for the CBD-Intein-ADI fusion protein is synthesized and cloned into the vector under the control of the T7 promoter for expression in E. coli (FIG. 4D). The CBD-InteinADI fusion protein produced binds to chitin in a column. The amino acid sequence of the CBDIntein-ADI (SEQ ID NO: 43) is shown in FIG. 4B. After cleavage at pH 7 and 25°C, and elution from the column, the ADI with α-cysteine at its N-terminus is obtained (FIG. 4D). Finally, the AAD fusion protein is produced by the protein ligation reaction as shown in FIG. 4E.
[0032] Importantly, AAD fusion proteins can be produced and purified in a convenient manner. For example, an AAD fusion protein is successfully expressed and purified from E. coli both in soluble fraction and insoluble fraction, and this resuit is shown in FIG. 8. Furthermore, FIG. 8 shows the purified AAD fusion protein analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The size of the purified AAD fusion protein is determined as 52.8 kDa.
[0033] The pharmaceutical composition of the présent invention contains AAD fusion protein with high activity for depleting arginine in tumor cells for cancer treatment. The spécifie activity of the purified AAD fusion protein is found to be similar to that of the wild-type ADI. IC50 is the half maximal inhibitory concentration, that is, it represents the concentration of AAD fusion protein that is required for 50% inhibition of a cancer cell line. The IC50 is a measure of the effectiveness of a drug. The IC50 of AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) for different cancer cell lines (human melanoma, A375 & SK-mel-28; human colon carcinoma, HCTl 16; human pancreatic cancer, Panel; human liver cancer, Sk-hepl; human cervical cancer, C-33A) is shown in TABLE 1. The in vitro efficacy of AAD fusion protein on different cancer cell lines is demonstrated in FIG. 9. It illustrâtes that AAD fusion protein can kill many cancer types, including human melanoma, human colon carcinoma and pancreatic cancer cell lines.
[0034] TABLE 1
Cancer cell line | IC50 of AAD (μ§/ιη1) |
A375 (human melanoma) | 0.104 |
SK-mel-28 (human melanoma) | 1.92 |
Panel (human pancreatic cancer) | 1 |
Sk-hepl (human liver cancer) | 10 |
C-33A (human cervical cancer) | 0.063 |
HCT116 (human colon carcinoma) | 1.30 |
[0035] For the albumin binding study, we hâve demonstrated successfully that the engineered
AAD fusion protein can bind to human sérum albumin (HSA). FIG. 10 shows that the AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) binds to HSA readily. At a mole ratio of 1:5 or 1:15, the formation of the HSA-AAD complex forms according to the construct of FIG. 1 using the linker molécule design. It is expected that the circulating half-life of 10 AAD fusion protein in the blood is increased by the non-covalent HSA-AAD complex formation.
Therefore, a long-lasting version of AAD fusion protein has been successfully created.
[0036] No commercial products show high efficacy when compared to the AAD fusion proteincontaining pharmaceutical composition prepared in this invention. For uses in cancer treatment, the AAD fusion protein-containing pharmaceutical composition of the présent invention serves 15 as an anti-cancer agent to deplete the arginine in tumor tissues. AAD fusion protein is a good candidate to be used in combination with other molecular targeting or cytotoxic agents.
Examples [0037] The following examples are provided by way of describing spécifie embodiments of this invention without intending to limit the scope of this invention in any way.
[0038] Several of the Examples below relate to methods of making an albumin-binding arginine deiminase fusion protein. Various techniques can be used including cloning and intein-mediated protein ligation. As used herein, the term “cloning” is broadly used and comprises constructing a fusion gene coding for the albumin-binding arginine deiminase fusion protein, inserting the fusion gene into a vector, inserting the vector into a host organism and expressing a protein that includes an albumin-binding arginine deiminase fusion protein. Numerous variants on this technique can be performed and still fall within the cloning contemplated by the présent invention.
[0039] Example 1 [0040] Construction of the gene coding for albumin-binding domain/peptide/protein (ABD) [0041] The gene coding for ABD is constructed by two rounds of PCR. In the first round, the PCR reaction mixture (total volume of 25 μΐ) contains the following materials:
x iProof PCR buffer (Bio-Rad) μΜ dNTP mixture
0.5 unit of iProof DNA Polymerase (Bio-Rad) nM of each of the following oligos
ABD-F1 forwardprimer (SEQ ID NO: 01):
5' -CATGATGCGAATTCCTTAGCTGAAGCTAAAGTCTTAGCTAACAGAGAACT-3 '
ABD-R2 reverse primer (SEQ ID NO: 02):
' -TAGTCACTTACTCCATATTTGTCAAGTTCTCTGTTAGCTAAGACTTTAGC-3 '
ABD-F3 forwardprimer (SEQ ID NO: 03):
' -GAACTTGACAAATATGGAGTAAGTGACTATTACAAGAACCTAATCAACAA-3 '
ABD-R4 reverse primer (SEQ ID NO: 04):
' -TACACCTTCAACAGTTTTGGCATTGTTGATTAGGTTCTTGTAATAGTCAC-3 '
ABD-F5 forwardprimer (SEQ ID NO: 05):
' -GCCAAAACTGTTGAAGGTGTAAAAGCACTGATAGATGAAATTTTAGCTGC - 3 '
ABD-R6 reverse primer (SEQ ID NO: 06):
' - AGCTACGATAAGCTTAAGGTAATGCAGCTAAAATTTCATCTATCAGTG - 3 '
The following PCR program is used:
98°C 30 s; 20 cycles of {98°C 10 s, 50°C 20 s, 72°C 20 s} [0042] In the second round of PCR, the PCR mixture (total volume of 50 μΐ) contains the following materials:
x iProof PCR buffer (Bio-Rad);
μΜ dNTP mixture;
μΐ of PCR reactant as DNA template from the first round;
unit of iProof DNA Polymerase (Bio-Rad);
200 nM of each of the following oligos:
ABD-F7forwardprimer (SEQ ID NO: 07):
5' -CATGATGCGAATTCCTTAGCTGAAGCTAAAGTCTTAGCTAACAGAGAACT-3 '
ABD-R8 reverse primer (SEQ ID NO: 08):
' -AGCTACGATAAGCTTAAGGTAATGCAGCTAAAATTTCATCTATCAGTG- 3 '
The following PCR program is used:
98°C 30 s; 35 cycles of {98°C 10 s, 60°C 20 s, 72°C 20 s}; 72°C 5 min [0043] A PCR product containîng the DNA sequence of ABD (169 bp) is obtained and purified by Qiagen DNA Gel Extraction Kit for cloning purpose.
[0044] Example 2A [0045] Construction of the fusion gene coding for the AAD fusion protein [0046] In the first PCR, the PCR mixture (total volume of 50 μΐ) contains the following materials:
x iProof PCR buffer (Bio-Rad);
μΜ dNTP mixture;
ng of Mycoplasma arginini genomic DNA; gb l unit of iProof DNA Polymerase (Bio-Rad);
200 nM of each of the following oligos:
ADINde-Fforwardprimer (SEQ ID NO: 09):
' -ATCGATCGATGTCTGTATTTGACAGTAAATTTAAAGG- 3 ’
ADIhis-R reverse primer (SEQ ID NO: 10):
’ -AGCTAAGGAATTCGCATCATGATGGTGATGGTGGTGGCTACCCCACTTAAC-3 '
The following PCR program is used:
98°C 1 min; 35 cycles of {98°C 10s, 50°C 20s, 72°C 40s}; 72°C 5 min
A PCR product of 1280 bp long is obtained and purified by Qiagen DNA Gel Extraction Kit. After that, the second PCR is performed. The PCR mixture (total volume of 50 μΐ) contains the following materials:
x iProof PCR buffer (Bio-Rad);
μΜ dNTP mixture;
ng of the 1280 bp PCR product;
ng of the 169 bp PCR product;
unit of iProof DNA Polymerase (Bio-Rad);
200 nM of each of the following oligos:
ADINde-Fforwardprimer (SEQ ID NO: 11):
' -ATCGATCGATGTCTGTATTTGACAGTAAATTTAAAGG- 3 '
ABD-R10 reverse primer (SEQ ID NO: 12):
' -AGCTACGATAAGCTTAAGGTAATGCAGCTAAAATTTCATCTATCAGTG-3 '
The following PCR program is used:
98°C 1 min; 35 cycles of {98°C 10s, 50°C 20s, 72°C 45s}; 72°C 5 min [0047] A PCR product of 1428 bp is obtained and purified by Qiagen DNA Gel Extraction Kit. Then it is digested with restriction enzymes Ndel and HindlII, and ligated to plasmid pREST A (Invitrogen) that is predigested with the same enzymes. The ligation product is then transformed into E. coli BL21 (DE3) cells. The sequence of the constructed fusion gene is confirmed by DNA sequencing.
[0048] Example 2B [0049] Cloning of His-ABD-PolyN-ADI [0050] The construction of His-ABD-PolyN-ADI (SEQ ID NO: 40, in FIG. 3E) is done by two steps of overlapping PCR, the PCR fragment obtained from the last step is inserted into the vector pET3a between the Ndel and BamHI sites. The gene map, nucléotide sequence and amino acid sequence of His-ABD-PolyN-ADI are shown in FIG. 6.
Primers involved in construction of His-ABD-PolyN-ADI:
hisABDNde-Fforwardprimer (SEQ ID NO: 13):
' -GGAGATATACATATGCATCATCACCATCACCATGATGAAGCCGTGGATG- 3 '
ABDnn-Rl reverse primer (SEQ ID NO: 14):
' -TTGTTATTATTGTTGTTACTACCCGAAGGTAATGCAGCTAAAATTTCATC- 3 ’
ABDn-R2 reverse primer (SEQ ID NO: 15):
’ -AGAACCGCCGCTACCATTGTTATTATTGTTGTTACTACCCGA- 3 ’
ADln-Fforwardprimer (SEQ ID NO: 16):
’ -AATAATAACAATGGTAGCGGCGGTTCTGTATTTGACAGTAAATTTAAAGG-3 '
ADIBam-R reverse primer (SEQ ID NO: 17):
’ -TAGATCAATGGATCCTTACCACTTAACATCTTTACGTGATAAAG-3 ' [0051] In the first round of PCR, 50 μΐ of reaction volume contaîning the known concentration of components are prepared in two PCR tubes. In each of the tubes, dNTP, iProof buffer (BIORAD), iProof DNA polymerase (BIO-RAD), primers and DNA template are mixed and added up to 50 μΐ by ddl^O. The DNA template used in the reaction is a pET3a vector contaîning the gene jZ'' of ADI from Mycoplasma arginini with a removal of an internai Ndel site mutation without altering the protein sequence of the ADI gene.
[0052] The two reaction tubes contain the primer mixtures of (A) 10 pmol hisABDNde-F (SEQ ID NO: 13), 0.5 pmol ABDnn-Rl (SEQ ID NO: 14) and 10 pmol ABDn-R2 (SEQ ID NO: 15); and (B) 10 pmol ADIn-F (SEQ ID NO: 16) and 10 pmol ADIBam-R (SEQ ID NO: 17), respectively.
[0053] The PCR program is set according to the recommended steps in the manual with an annealing and extension température (time) at 50 °C (20 s) and 72 °C (40 s), respectively. The two products generated by PCR with the size of 237 bp and 1278 bp. The products are extracted and applied as template for the next round of PCR.
[0054] In the second overlapping step, the reaction mixture is prepared in a similar way to the first round except the template used was the mixture of 1 pmol of the 237 bp PCR product and 1 pmol of the 1278 bp PCR product from the first round PCR. Primers used are changed to 10 pmol hisABDNde-F (SEQ ID NO: 13) and 10 pmol ADIBam-R (SEQ ID NO: 17).
[0055] The annealing and extension température (time) are 50 °C (20 s) and 72 °C (60 s), respectively. A PCR product with the size of 1484 bp is generated from the reaction. The PCR product is purified and digested with Ndel and BamHI and then ligated into the pre-digested pET3a plasmid. The ligated product is then transformed into E. coli BL21 (DE3) for the production of recombinant protein.
[0056] Example 2C [0057] Cloning of His-ABD-PolyN-bcADI [0058] The construction of His-ABD-PolyN-bcADI (SEQ ID NO: 41, in FIG. 3F) is done by two steps of overlapping PCR, the PCR fragment obtained from the last step is inserted into the vector pET3a between the Ndel and BamHI sites. The gene map, nucléotide sequence and amino acid sequence of His-ABD-PolyN-bcADI are shown in FIG. 7.
Primers involved in construction of His-ABD-PolyN-bcADI:
hisABDNde-F2 forwardprimer (SEQ ID NO: 18):
5' -GGAGATATACATATGCATCATCACCATCACCATGATGAAGCCGTGGATG-3' bcABDnn-Rl reverse primer (SEQ ID NO: 19):
’ -TTGTTATTATTGTTGTTACTACCCGAAGGTAATGCAGCTAAAATTTCATC- 3 ’ bcABDn-R2 reverse primer (SEQ ID NO: 20):
' -TTTACCGCCGCTACCATTGTTATTATTGTTGTTACTACCCGA-3 ' bcADln-Fforwardprimer (SEQ ID NO: 21):
' -AATAATAACAATGGTAGCGGCGGTAAACATCCGATACATGTTACTTCAGA- 3 ' bcADIBam-R reverse primer (SEQ ID NO: 22):
' -TAGATCAATGGATCCCTAAATATCTTTACGAACAATTGGC ATAC- 3 ' [0059] In the first round of PCR, 50 μΐ of reaction volume containing the known concentration of components are prepared in two PCR tubes. In each of the tubes, dNTP, iProof buffer (BIORAD), iProof DNA polymerase (BIO-RAD), primers and DNA template are mixed and added up to 50 μΐ by ddHîO. The DNA template used in the reaction is a pET3a vector containing the gene of ADI from Bacillius cereus with a removal of an internai Ndel site mutation without altering the protein sequence of the ADI gene.
[0060] The two reaction tubes contain the primer mixtures of (A) 10 pmol hisABDNde-F2 (SEQ ID NO: 18), 0.5 pmol bcABDnn-Rl (SEQ ID NO: 19) and 10 pmol bcABDn-R2 (SEQ ID NO: 20); and (B) 10 pmol bcADIn-F (SEQ ID NO: 21) and 10 pmol bcADIBam-R (SEQ ID NO: 22), respectively. The PCR program is set according to the recommended steps in the manual with an annealing and extension température (time) at 50 °C (20 s) and 72 °C (40 s), respectively. The two products are generated by PCR with the size of 237 bp and 1250 bp. The products are extracted and applied as template for the next round of PCR.
[0061] In the second overlapping step, the reaction mixture is prepared in a similar way to the first round except the template used is the mixture of 1 pmol of the 237 bp PCR product and 1 pmol of the 1250 bp PCR product from the first round PCR. Primers used are changed to 10 pmol hisABDNde-F2 (SEQ ID NO: 18) and 10 pmol bcADIBam-R (SEQ ID NO: 22).
[0062] The annealing and extension température (time) are 50 °C (20 s) and 72 °C (60 s), respectively. A PCR product with the size of 1512 bp is generated from the reaction. The PCR Y product is purified and digested with Ndel and BamHl and then ligated into the pre-digested pET3a plasmid. The ligated product is then transformed into E. coli BL2l (DE3) for the production of recombinant protein.
[0063] Example 3 [0064] Expression and purification of the AAD fusion protein [0065] For preparing the seed culture, the strain E. coli BL2l(DE3) carrying the plasmid encoding the AAD fusion protein (FIG. 5) is eultured in 5 ml of 2xTY medium, 30°C, 250 rpm, ovemight. The ovemight seed culture (2.5 ml) is added to 250 ml of 2xTY, 37°C, 250 rpm, 2.5 h (until ODéoo ~ 0.6-0.7). When the ODôoo reached, IPTG is added to the culture (0.2 mM final concentration). The growth is continued for 22 more hours at 20°C and then the cells are collected by centrifugation. The cell pellet is resuspended in 25 ml of 10 mM sodium phosphate buffer, pH 7.4. The cells are lysed by sonication. The soluble portion is collected after centrifugation. The fusion protein (containing a His tag) is then purified by nickel affinity chromatography. TABLE 2 shows that cultivation température is an important factor in affecting the solubility of AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) obtained from the expression host.
[0066] For isolating the soluble fraction of AAD fusion protein, the cell pellet is resuspended in 25 ml of 10 mM sodium phosphate buffer, pH 7.4. The cells are lysed by sonication. The soluble portion is collected after centrifugation. The AAD fùsion protein (contains a His tag) is then purified by nickel affinity chromatography.
[0067] For isolating the insoluble fraction of AAD fusion protein, the cell pellet is resuspended in 25 ml of 20 mM Tris-HCl, pH 7.4, 1% Triton X-100. The cells are lysed by sonication. The insoluble portion (inclusion bodies) is collected by centrifugation. The protein is unfolded by resuspending in 10 ml of 20 mM Tris-HCl, pH 7.4, 6 M Guanidine HCl, and vortexed until it becomes soluble. The protein is refolded by adding the unfolded protein solution drop by drop into a fast stirring solution of 100 ml of 20 mM Sodium phosphate buffer, pH 7.4. The insoluble materials are removed by centrifugation. Salting out of the protein is performed by adding solid ammonium sulphate powder into the supernatant to achieve 70% saturation. The insoluble portion is collected by centrifugation and it is resuspended in 10 ml of 20 mM sodium phosphate buffer. The AAD fusion protein (contains a His tag) is then purified by nickel affinity chromatography.
[0068] TABLE 2
AAD | 1 | 2 | 3 |
Cultivation température (°C) | 30 | 20 | 37 |
Yield (mg) / 250ml culture | -0.66 | -12.0 | -7.0 |
solubility | 50% soluble | 90% soluble | 90% inclusion body |
IC50 (gg/ml) on A375 cells | 0.10 | 0.68 | 0.23 |
[0069] Example 4 [0070] Enzyme activity assay and Enzyme kinetics for AAD fusion protein [0071] To détermine the enzyme activity for wild-type ADI and AAD fusion protein in the présent invention, the diacetyl monoxime (DAM) - thiosemicarbazide (TSC) assay for citrulline détection is used. The reaction is shown below.
[0072] L-Arginine or aad fusion protein > L_Citrulline + Ammonia [0073] This assay is run by adding sample to a color reagent, which is made by mixing acidic ferrie chloride solution with DAM-TSC solution. Briefly, enzyme is incubated with 20 mM arginine, 10 mM sodium phosphate pH 7.4 for 5 min at 37°C. The reaction mixture is heated at 100°C for 5 min to develop the color and read at 540 nm (light path = 1 cm). A standard curve is constructed using various concentrations of citrulline. One unit of the ADI native enzyme is the amount of enzyme activity that converts 1 pmol of arginine to 1 pmol of citrulline per minute at 37°C under the assay conditions. The spécifie activities of wild-type ADI and AAD fusion protein in the présent invention are 8.4 and 9.2 U/mg (at pH 7.4, physiological pH) respectively. The spécifie activities for wild-type ADI and AAD fusion protein at different pH range (from pH 5.5 to 9.5) are also determined, and the optimum pH is at 6.5. Therefore, the results indicate that AAD fusion protein depletes arginine efficiently, as the fusion with albumin-binding protein does not affect enzyme activity of ADI. vkA [0074] The Michaelis constant Km is the substrate concentration at which the reaction rate is at half-maximum, and is an inverse measure of the substrate's affinity for the enzyme. A small Km indicates high affinity for the substrate, and it means that the rate will approach the maximum reaction rate more quickly. For détermination of the enzyme kinetics or Km value, the activity of wild-type ADI and AAD fusion protein are measured under different concentration of substrate arginine (2000 μΜ, 1000 μΜ, 500 μΜ, 250 μΜ, 125 μΜ, 62.5 μΜ) at ρΗ 7.4. The measured Km values of the AAD fusion protein shown in FIG. 3E (SEQ ID NO: 40, ADI protein is originated from Mycoplasma arginini) and AAD fusion protein shown in FIG. 3F (SEQ ID NO: 41, ADI protein is originated from Bacillus cereus) are 0.0041 mM and 0.132 mM respectively. The results suggest that the fusion to ABD did not affect the binding affinity of the different AAD fusion proteins to arginine.
[0075] Example 5 [0076] Cell prolifération assay and in vitro effïcacy of AAD fusion protein on cancer cell lines [0077] Culture medium DMEM is used to grow the human melanoma A375 & SK-mel-28, human pancreatic cancer Panel and human cervical cancer C-33A cell lines. The EMEM medium is used to culture the SK-hep 1 liver cancer and C-33A cervical cancer cell line. Cancer cells (2-5 X 103) in 100 μΐ culture medium are seeded to the wells of 96-well plates and incubated for 24 h. The culture medium is replaced with medium containing different concentrations of AAD fusion protein. The plates are incubated for an additional 3 days at 37°C in an atmosphère of 95% air/5% CO2. MTT assay is performed to estimate the number of viable cells in the culture according to manufacturer’s instructions. The amount of enzyme needed to achieve 50% inhibition of cell growth is defined as IC50.
[0078] As shown in TABLE 1 and FIG. 9, the results indicate that AAD fusion protein depletes arginine efficiently and inhibits the growth of various types of human cancer cell lines in in vitro tissue culture studies. For example, human melanoma, human colon carcinoma, human pancreatic cancer, human liver cancer and human cervical cancer, ail hâve low values of IC50 (see TABLE 1), as these cancer types are ail inhibited by AAD fusion protein readily. As predicted, AAD fusion protein would inhibit ail cancer types that are arginine-dependent (for example, the ASS-negative cancers). vY [0079] Example 6 [0080] In vivo half-life détermination of AAD fusion protein [0081] Balb/c mice (5-7 weeks) are used in this study and they are allowed to acclimatize for a week before the experiment. Mice (n=3) are separated into four groups and injected with 0, 100, 500 or 1000 pg of AAD fusion protein (SEQ ID NO: 40, FIG. 3E) in 100 μΐ PBS intraperitoneally, respectively. Blood of each mouse is collected at 0 h and Day 1-7. Sera are obtained after centrifugation. The sera are then deproteinised and analyzed by amino acid analyzer for arginine.
[0082] As shown in FIG. 11, AAD fusion protein (SEQ ID NO: 40, FIG. 3E), even at the lowest dosage of 100 pg, depletes plasma arginine efficiently at Day 1, 3 and 5, suggesting that AAD can deplete arginine in vivo efficiently for at least 5 days. The arginine level retums to normal gradually at Day 6 and Day 7 in ail treatment groups.
[0083] Example 7 [0084] In vivo efficacy of AAD fusion protein on cancer cell xenografts [0085] Nude balb/c mice (5-7 weeks) are used in this study and they are allowed to acclimatize for a week before the experiment. Mice are inoculated subcutaneously with 2x106 cancer cells in 100 μΐ of fresh culture medium. Ten days later, the mice are randomly separated into control and treatment group. Control group receives 100 μΐ PBS and treatment group receives 100 μΐ AAD fusion protein intraperitoneally weekly. Tumor size is measured by caliper and tumor volume is calculated using formula: (length x width2)/2. Blood draw are obtained at Day 5 after each treatment for plasma measurement of arginine.
Claims (28)
1. An albumin-binding arginine deiminase fusion protein comprising a first portion comprising one or two components selected from an albumin-binding domain, an albumin-binding peptide or an albumin-binding protein(s) fused to a second portion comprising arginine deiminase to form the albumin-binding arginine deiminase fusion protein, and one or more linker molécules; the first portion being positioned far from active site of the second portion by said linker molécule such that the albumin-binding arginine deiminase fusion protein retains the activity of arginine deiminase and binds sérum albumin with neither function of one portion of the fusion protein being interfered with by the other portion of the fusion protein, wherein the albuminbinding arginine deiminase fusion protein comprises an amino acid sequence selected from SEQ ID NO: 36, 37, 38, 39, 40, or 4L
2. An albumin-binding arginine deiminase fusion protein according to claim l wherein the two components are the same.
3. An albumin-binding arginine deiminase fusion protein according to claim l wherein the two components are different.
4. An albumin-binding arginine deiminase fusion protein according to claim l wherein the albumin-binding domain is SEQ ID NO. 46, 47, 48, 49 or an active portion thereof.
5. An albumin-binding arginine deiminase fusion protein according to claim 1 wherein the albumin binding peptide is SEQ ID NO. 46, 47, 48, 49 or an active portion thereof.
6. An albumin-binding arginine deiminase fusion protein according to claim 1 wherein the albumin binding protein is SEQ ID NO. 46, 47, 48, 49 or an active portion thereof.
7. An albumin-binding arginine deiminase fusion protein according to claim 1 wherein the linker molécule includes a sequence selected from SEQ ID NO. 50, 51, 52, 53, or serine-glycineserine (SGS) amino acid sequence.
8. An albumin-binding arginine deiminase fusion protein according to claim l further comprising at least one of Poly-N or a His tag.
9. An albumin-binding arginine deiminase fusion protein according to claim 1 wherein the fusion includes a remaining portion of an intein-mediated protein ligation between the first portion and the second portion.
10. An albumin-binding arginine deiminase fusion protein according to claim 9 wherein the intein-mediated protein includes a chitin binding domain.
11. An albumin-binding arginine deiminase fusion protein according to claim 1 wherein the arginine deiminase is selected from arginine deiminase produced from a Mycoplasma, Lactococcus, Pseudomonas, Steptococcus, Escherichia, Mycobacterium or Bacillus microorganism.
12. An albumin-binding arginine deiminase fusion protein according to claim 11 wherein the arginine deiminase is produced from Mycoplasma arginini, Lactococcus lactis, Bacillus licheniforrais, Bacillus cereus, Mycoplasma arthritidis, Mycoplasma hominis, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pneumoniae, Mycobacterium tuberculosis, Pseudomonas plecoglossicida, Pseudomonas putida, Pseudomonas aeruginosa or a combination thereof.
13. An albumin-binding arginine deiminase fusion protein according to claim 1 wherein the fusion protein is formed by reacting the arginine deiminase having a N-terminal cysteine residue with a reactive thioester at C-terminus of the albumin-binding domain so that the arginine deiminase and the albumin-binding domain are linked by a covalent bond.
14. An albumin-binding arginine deiminase fusion protein according to claim 1 wherein the fusion protein is formed by reacting the albumin-binding domain having a N-terminal cysteine residue with a reactive thioester at C-terminus of the arginine deiminase so that the arginine deiminase and the albumin-binding domain are linked by a covalent bond. Λ/-
15. An albumin-binding arginine deiminase fusion protein according to claim l wherein the fusion protein is formed by using SEQ ID NOS. 42 and 43 and by reacting the arginine deiminase having a N-terminal cysteine residue with a reactive thioester at C-terminus of the albumin-binding domain so that the arginine deiminase and the albumin-binding domain are linked by a covalent bond.
16. Use of the albumin-binding arginine deiminase fusion protein according to any one of claims 1 to 15 in préparation of a médicament for treating a cancer in a patient comprising administering a clinically effective amount of the fusion protein to the patient to reduce the availability of circulating arginine.
17. The use according to claim 16 wherein the cancer is pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer or brain cancer.
18. Use of the albumin-binding arginine deiminase fusion protein according to any one of claims 1 to 15 in préparation of a médicament for treating arginine-dependent diseases in a patient comprising administering a clinically effective amount of the fusion protein to the patient to reduce the availability of circulating arginine.
19. A method of making the albumin-binding arginine deiminase fusion protein of claim 1 comprising constructing a fusion gene coding for the albumin-binding arginine deiminase fusion protein, inserting the fusion gene into a vector, inserting the vector into a host organism and expressing a protein including the albumin-binding arginine deiminase fusion protein of claim 1.
20. The method of making the albumin-binding arginine deiminase fusion protein according to claim 19 further comprising purifying the fusion protein.
21. The method of making the albumin-binding arginine deiminase fusion protein according to claim 20 wherein the purifying is performed by chromatography.
22. The method of making the albumin-binding arginine deiminase fusion protein according to claim 20 wherein the purifying is performed from soluble fractions of crude proteins.
23. The method of making the albumin-binding arginine deiminase fusion protein according to claim 20 wherein the purifying is performed from insoluble fractions of crude proteins.
24. A method of making the albumin-binding deiminase fusion protein of claim l by intein mediated protein ligation between the albumin-binding domain, albumin-binding peptide or albumin-binding protein(s) and the second portion comprising arginine deiminase.
25. A pharmaceutical composition comprising the albumin-binding arginine deiminase fusion protein of claim l in a pharmaceutically-acceptable carrier.
26. The pharmaceutical composition of claim 25 wherein the composition has a pH in a range of
5.5 to 9.5.
27. The pharmaceutical composition of claim 25 wherein the composition has a pH of 7.4.
28. The pharmaceutical composition of claim 25 wherein the composition has a pH of 6.5. tfj'
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/773214 | 2013-03-06 | ||
US14/197236 | 2014-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17472A true OA17472A (en) | 2016-12-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE47233E1 (en) | Albumin-binding arginine deiminase and the use thereof | |
Sannikova et al. | The modified heparin-binding L-asparaginase of Wolinella succinogenes | |
JP7091248B2 (en) | L-asparaginase mutants and fusion proteins with reduced L-glutaminase activity and enhanced stability | |
KR20230017804A (en) | RHFGF21 fusion proteins, polynucleotides encoding RHFGF21 fusion proteins, compositions comprising RHFGF21 fusion proteins, and uses of RHFGF21 fusion proteins | |
WO2013056657A1 (en) | Activity-enhanced l-asparaginase variant | |
JP2023543045A (en) | Uric acid oxidase-albumin conjugate, its production method and uses | |
EP3664832B1 (en) | Truncated guinea pig l-asparaginase variants and methods of use | |
USRE48805E1 (en) | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein | |
US9051562B2 (en) | Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer | |
OA17472A (en) | Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment. | |
NZ711234B2 (en) | Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment | |
ES2753962T3 (en) | Isolated polypeptides of Brevibacterium aurantiacum and their use for the treatment of cancer |